BioCardia Initiates Commercial Release of AVANCE Steerable Introducer Designed to Enhance Physician Control for Complex Cardi...
October 01 2019 - 8:00AM
BioCardia (Nasdaq: BCDA), a leader in the development of
comprehensive solutions for cardiovascular regenerative therapies,
today announced the U.S. commercial availability of its AVANCE™
Bi-Directional Steerable Introducer Sheath for introducing various
cardiovascular catheters into the heart, including via the left
side of the heart through the interatrial septum. The product
became available in late September.
An introducer sheath is routinely used by electrophysiologists
(EPs) and interventional cardiologists (ICs) to facilitate complex
conditions such as atrial fibrillation and structural heart
procedures. The AVANCE™ device addresses the
shortcomings of currently available steerable introducers with its
unique patent protected “Morph DNA” technology creating a high
performance steerable introducer for superior control during
complex procedures.
The AVANCE catheter is designed to have uniform bending
characteristics in all directions by having the two tendon wires
wrap helically around the catheter shaft, like the double helix in
DNA. The uniform bending characteristics where critically
important are intended to reduce what EPs and ICs refer to as
“whip” in catheter navigation, where the catheter jumps to a new
location in an uncontrolled fashion.
The product is designed with a smooth tip-to-dilator transition
which promotes ease of entry into the left atrium during
transseptal access. Deflections of 180 degrees in both directions
are designed to provide increased steerability, which may improve
access to hard-to-reach sites.
The AVANCE™ device was recently used on a patient at John F.
Kennedy Hospital (JFK) in West Palm Beach, Florida.
“One of our overall goals is to enhance procedural control by
improving products used during procedures,” said Robert Fishel, MD,
director of Electrophysiology at JFK. “The AVANCE product performed
well in our hands and we found it competitive.”
“The AVANCE product incorporates a significant advance in
catheter technology,” said BioCardia CEO Peter Altman, PhD. “ Our
team developed the rotating pull wire technology for our cell
therapy procedures in the left ventricle of the heart and
recognized that it could also significantly benefit patients by
enhancing physician control in complex cardiac procedures.”
The AVANCE device will have a limited launch while the company
seeks feedback from EPs and ICs on real-world use and explores
options for manufacturing at scale.
Procedures that leverage transseptal delivery include atrial
fibrillation ablation, patent foramen ovale (PFO) and atrial septal
defect (ASD) repair, percutaneous mitral valve repair, left atrial
appendage closure, and percutaneous left ventricular assist device
placement, among others. The global transseptal access systems
market value is currently estimated at $490 million and is expected
to increase at a compound annual growth rate (CAGR) of 10.4 percent
from 2017 to 2024.1
About BioCardia®
BioCardia, Inc., headquartered in San Carlos, California,
is developing regenerative biologic therapies to treat
cardiovascular disease. CardiAMP™ and CardiALLO™ cell therapies are
the Company’s biotherapeutic product candidates in clinical
development. The Company's current products include the Helix™
Biotherapeutic Delivery System and the Morph® steerable guide and
sheath catheter portfolio, including the new AVANCE™ Steerable
Introducer family. BioCardia also partners with other
biotherapeutic companies to provide its Helix systems and clinical
support to their programs studying therapies for the treatment of
heart failure, chronic myocardial ischemia and acute myocardial
infarction.
Forward Looking Statements: This press release
contains forward-looking statements that are subject to many risks
and uncertainties. Forward-looking statements include statements
regarding our intentions, beliefs, projections, outlook, analyses
or current expectations. Such factors include, among others, the
inherent uncertainties associated with developing new products or
technologies, regulatory approvals, unexpected expenditures, the
ability to raise the additional funding needed to continue to
pursue BioCardia’s business and product development plans and
overall market conditions. These forward-looking statements are
made as of the date of this press release, and BioCardia assumes no
obligation to update the forward-looking statements.
We may use terms such as “believes,” “estimates,” “anticipates,”
“expects,” “plans,” “intends,” “may,” “could,” “might,” “will,”
“should,” “approximately” or other words that convey the
uncertainty of future events or outcomes to identify these
forward-looking statements. Although we believe that we have a
reasonable basis for each forward-looking statement contained
herein, we caution you that forward-looking statements are not
guarantees of future performance and that our actual results, and
the development of the industry in which we operate may differ
materially from the forward-looking statements contained in this
presentation. As a result of these factors, we cannot assure you
that the forward-looking statements in this press release will
prove to be accurate. Additional factors that could materially
affect actual results can be found in BioCardia’s
Form 10-Q filed with the Securities and Exchange
Commission on August 9, 2019, including under the caption titled
“Risk Factors.” BioCardia expressly disclaims any intent or
obligation to update these forward-looking statements, except as
required by law.
1. Persistence Market Research (2017). “Transseptal Access
Systems Market: Global Industry Analysis (2012-2016) and Forecast
(2017-2025).” New York, NY. Persistence Market Research Pvt.
Ltd.
INVESTOR CONTACT: David McClung, Chief
Financial Officer investors@BioCardia.com (650) 226-0120
MEDIA CONTACT: Michelle McAdam, Chronic
Communications, Inc. michelle@chronic-comm.com (310) 545-6654
BioCardia (NASDAQ:BCDA)
Historical Stock Chart
From Mar 2024 to Apr 2024
BioCardia (NASDAQ:BCDA)
Historical Stock Chart
From Apr 2023 to Apr 2024